Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment
Recruitment status was Recruiting
The purpose of the study is to assess the functional outcome, quality of life and late sequelae in a representative sample of 1100 long-term survivors of Ewing sarcoma and to build a unique clinical and functional data pool of the underlying cohort of 3000 Ewing sarcoma patients with a follow-up of 3 decades.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment|
- real-world daily activity (SAM: step-activity-monitor) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
- health-related quality of life (SF36, PEDQOL) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
- functional status (TESS) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
- psychological status (HADS, BIS-BAS) [ Time Frame: 5-30years after primary diagnosis of Ewing sarcoma ] [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Estimated Study Completion Date:||July 2014|
Trial objective: As survival rates of bone sarcoma patients have been raised owing to improved treatment strategies the focus of investigations is now on the medical, social, and economic sequelae of intensive multimodal treatment. This study aims to assess the functional outcome, quality of life and late sequelae in a representative sample of long-term survivors of Ewing sarcoma. The data recorded combined with standardized treatment data covering a 30-year period will produce a data pool that is unique for its magnitude and will be used for the development of guidelines for further improvements of future bone sarcoma treatment.
Working plan: The working plan provides for the assessment of functional outcome and quality of life by means of validated tools (TESS, SF36, PEDQOL) and objectively measuring daily activity patterns by using the Step Activity Monitor (SAM) in 1100 long-term Ewing sarcoma survivors and a control group of 1100 matched healthy subjects. Information on sarcoma treatment and follow-up is obtained by re-structuring and complementing the database of the relevant patient cohort (n=3000) from four consecutive nationwide and international clinical trials between 1980 and 2008. Procedures of local treatment will be evaluated regarding functional outcome, quality of life, and survival probability and prognostic factors predicting long-term outcome will be identified.
Exploitation of results: The results will be presented at scientific meetings and will be published in international journals. Guidelines will be developed regarding improvements in the treatment, rehabilitation, and social integration of bone sarcoma patients to be utilized in guiding patients and in the decision process of medical professionals regarding their treatment. In the long run, the evidence based guidelines on treatment and follow-up are to be transferred into the health system.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00824083
|Contact: Andreas Ranft, Dr.||firstname.lastname@example.org|
|Contact: Christiane Hoffmann, Dr.||0049-251-8356485||Christiane.Hoffmann@ukmuenster.de|
|Department of Pediatric Hematology and Oncology, University Children's Hospital||Recruiting|
|Muenster, North Rhine Westphalia, Germany, 48129|
|Contact: Andreas Ranft, Dr. 0049-251-8356486 email@example.com|
|Contact: Christiane Hoffmann, Dr. 0049-251-8356485 Christiane.Hoffmann@ukmuenster.de|
|Principal Investigator: Heribert Jürgens, Prof.|
|Motion Analysis Lab, Orthopedic Department, University Hospital||Recruiting|
|Münster, North Rhine Westphalia, Germany, 48129|
|Contact: Corinna Winter, MA 0049-251-8352975 firstname.lastname@example.org|
|Contact: Dieter Rosenbaum, Prof. 0049-251-8352970 email@example.com|
|Principal Investigator: Dieter Rosenbaum, Prof.|
|Principal Investigator:||Heribert Jürgens, Prof.||University Hospital Muenster|
|Principal Investigator:||Dieter Rosenbaum, Prof.||University Hospital Muenster|